Earnings from its isotope products segment powered Eckert & Ziegler, parent company of radiotherapy and radioisotope developer Eckert & Ziegler Isotope Products, to a prosperous first quarter.
Revenues increased 9% to 28.2 million euros ($39.5 million U.S.), compared with 25.7 million euros ($36 million U.S.) in the first quarter of 2010. Net income advanced 44% to 3.6 million euros ($5 million U.S.), compared with 2.5 million euros ($3.5 million U.S.) in last year's first quarter.
The company's strongest growth was achieved by its radiopharmaceuticals business, where sales rose by at least 25% in every product group. The segment increased its quarterly revenue by 31% to 6.2 million euros ($8.7 million U.S.).
